CLINICAL TRIALS PROFILE FOR MECHLORETHAMINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for mechlorethamine hydrochloride
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00002462 ↗ | RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease | Active, not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | 1989-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with no radiation therapy following chemotherapy in treating patients with stage III or stage IV Hodgkin's disease. |
NCT00002463 ↗ | Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors | Completed | National Cancer Institute (NCI) | Phase 2 | 1989-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors. |
NCT00002463 ↗ | Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors | Completed | M.D. Anderson Cancer Center | Phase 2 | 1989-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors. |
NCT00002714 ↗ | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease | Completed | National Cancer Institute (NCI) | Phase 2 | 1995-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have early stage Hodgkin's disease. |
NCT00002714 ↗ | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease | Completed | Stanford University | Phase 2 | 1995-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have early stage Hodgkin's disease. |
NCT00002715 ↗ | Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1989-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for mechlorethamine hydrochloride
Condition Name
Clinical Trial Locations for mechlorethamine hydrochloride
Trials by Country
Clinical Trial Progress for mechlorethamine hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for mechlorethamine hydrochloride
Sponsor Name